Pharmacist-driven biosimilar substitution saves money

A study of pharmacist-driven substitution of brand-name biologicals with biosimilars has shown that this can lead to substantial cost savings in the setting of a community oncology practice.

The results of the study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held online on 4–8 June 2021.